论文信息 - The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization - 字舞流文

The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization

David T. Huang | C. Seymour | D. Angus | D. Yealy | G. Snyder | K. Kip | O. Marroquin | D. Nace | T. Khadem | S. Berry | Robert Bart | M. Schmidhofer | A. Weissman | B. McVerry | E. McCreary | J. Bariola | T. Minnier | R. J. Wadas | J. Shovel | D. Albin | M. Wisniewski | C. Sullivan | M. Axe | R. Meyers | K. Collins | A. Wells | K. Linstrum | S. Montgomery | G. Haidar | S. Koscumb | O. Peck-Palmer | L. Berry